C. Russell Trenary III has been at the helm of Outlook Therapeutics, Inc. as the President and CEO since July 2021. With decades of leadership in the medical devices field, he previously led InnFocus, a glaucoma medical device company, until...

C. Russell Trenary III has been at the helm of Outlook Therapeutics, Inc. as the President and CEO since July 2021. With decades of leadership in the medical devices field, he previously led InnFocus, a glaucoma medical device company, until its sale to Santen Pharmaceutical in 2020. He has also served as CEO for other companies focused on eye care and orthodontics. At Outlook Therapeutics, Trenary received a significant stock option grant of 4 million shares upon joining, which was tied to his performance and the company’s success. His compensation strategy is simple: a base salary of $600,000 plus potential bonuses tied to specific company performance goals. Despite a big year in 2021, his total earnings saw a drop in 2023, which reflects the company's evolving performance. C. Russell is not just an executive; he’s an insider with a depth of experience that drives the company’s vision forward. His expertise positions him as a key player in shaping Outlook’s innovative approach to medical solutions.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Outlook Therapeutics, Inc. CEOs

O

C. Russell Trenary III

Ex-CEO of Outlook Therapeutics, Inc.

Sector of Economy

Healthcare

CEO of Outlook Therapeutics, Inc. for

3 years 4 months (Jul 2021 - Dec 2024)

Previous Experience

President and CEO of InnFocus, Inc. until its acquisition by Santen Pharmaceutical.

Rivals

Competitors/colleagues of C. Russell Trenary III

Holdings

See how much did C. Russell Trenary III make over time.

C. Russell Trenary III holds around 2.22 million shares in Outlook Therapeutics, representing a modest ownership stake. This is backed by a substantial compensation package that includes options to purchase 4 million shares upon joining the company. While the majority...

C. Russell Trenary III holds around 2.22 million shares in Outlook Therapeutics, representing a modest ownership stake. This is backed by a substantial compensation package that includes options to purchase 4 million shares upon joining the company. While the majority of his stock options are still vesting, he has faced fluctuations in his potential wealth as stock performance changes. His compensation and shareholding strategy reflects a strong belief in the company's future, as he must continue to meet performance metrics to benefit from these options fully. Despite variability in stock value, his position serves as an essential alignment of interests between leadership and shareholders.

Insider Trading

See recent insider trades of C. Russell Trenary III.

OTLK

$21.12K

OTLK at $1.06/share

Jun 21, 2022

Purchase

OTLK

$34.75K

OTLK at $1.39/share

Dec 6, 2021

Purchase

OTLK

$14.00K

OTLK at $1.40/share

Dec 2, 2021

Purchase

Compensation History

See how much did C. Russell Trenary III make over time.

In 2023, C. Russell Trenary III recorded a compensation package totaling $1,758,862, which mainly consisted of his base salary of $600,000 and other benefits. However, his stock options granted have not yet vested. Back in 2022, his bonus of about $195,462 boosted his earnings, highlighting how performance can dramatically influence his pay. The compensation plan at Outlook is designed not only to reward Trenary's leadership but also to align his financial success with the company’s growth. This ensures he is incentivized to focus on long-term performance milestones, which are crucial for stakeholders looking for sustainable development in the industry.

Year

2023

Total Compensation

$610.90K

Salary

$600.00K

Board Justification

The compensation philosophy is designed to attract, reward, and retain executives necessary for the company's growth and profitability, aligning with shareholder interests.

Bonus

$0.00

Board Justification

No bonus was awarded for the year 2023.

Other

$10.90K

Board Justification

Includes payment of term life insurance premiums and 401(k) matching contributions.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2023 as the only options granted were not vested yet.

Performance Metrics

The performance metrics for determining compensation include the achievement of specific performance milestones related to stock options.

Other Outlook Therapeutics, Inc. CEOs

Here are other CEOs of Outlook Therapeutics, Inc.

Lawrence A. Kenyon

Ex-CEO of Outlook Therapeutics, Inc.

June 2018 - July 2021

Lawrence A. Kenyon

CEO of Outlook Therapeutics, Inc.

December 2024 - Present